Key Findings: Major CDMOs Boost Capacity with Strategic Investments and Regional Expansion
Fujifilm Diosynth has announced a substantial investment of approximately $2 billion to construct a new, state-of-the-art gene therapy manufacturing facility in North Carolina. This move is a strategic response to evolving geopolitical landscapes and shifts in global supply chains, reinforcing North American manufacturing capabilities. In parallel, leading CDMO Catalent, now under Novo Holdings, continues to broaden its OneBio manufacturing platform to encompass biologics, cell and gene therapy, and mRNA production, offering integrated solutions across a wide range of modalities. Significantly, India is rapidly solidifying its position as a crucial alternative global biopharmaceutical manufacturing hub, with GMP-grade capacity in major cities like Hyderabad, Bengaluru, and Pune expanding at an impressive annual growth rate of 27%.
Technical & Clinical Details: Requirements for Gene Therapy and Multi-Modality Platforms
Manufacturing gene therapy products demands advanced expertise in complex viral vector production—such as Adeno-Associated Virus (AAV) and lentiviral vectors—coupled with stringent GMP standards. Fujifilm Diosynth’s new facility is anticipated to integrate cutting-edge cleanroom technology, automation systems, and advanced quality control processes to meet these exacting requirements. Catalent’s OneBio platform provides the flexibility to support diverse biopharmaceutical modalities (e.g., antibodies, cell and gene therapies, mRNA vaccines) within a single site or an integrated network, accelerating client pipeline development. India’s manufacturing hubs are responding to global demand, particularly for biosimilars, generic biologics, and early-phase cell and gene therapy programs, by balancing cost-effectiveness with robust quality outputs.
Background & Industry Context: Supply Chain Diversification and CDMO’s Strategic Role
The global pandemic and ongoing geopolitical tensions have underscored the critical importance of resilience in biopharmaceutical supply chains. This has prompted many pharmaceutical companies to seek manufacturing diversification and regionalization, specifically aiming to reduce reliance on single regions like China. In this context, CDMOs are transcending their traditional role as mere manufacturing partners to become strategic providers of comprehensive supply chain solutions. Through substantial investments and technological innovation, CDMOs are proving indispensable in helping clients navigate manufacturing complexities and shorten time-to-market. India’s ascent as a manufacturing powerhouse symbolizes the maturing Asian market and the multipolarization of the global manufacturing ecosystem.
Strategic Significance & Outlook: Technology Integration and Intensified Global Competition
The biopharmaceutical manufacturing industry is expected to further enhance efficiency and quality through the integration of automation, digitalization, and AI-driven optimization. As gene therapy and mRNA technologies continue to advance, the demand for CDMOs with specialized manufacturing capabilities and expertise in these advanced modalities will steadily increase. In the highly competitive global CDMO market, technological innovation, cost competitiveness, and robust regulatory compliance will be key determinants of competitive advantage. The increasing strategic value of regional manufacturing hubs is anticipated to accelerate the delivery of innovative therapies to patients while simultaneously optimizing manufacturing costs, marking a transformative period for the industry.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments